September 21, 2018 — ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's MRIdian Linac. The MRIdian Linac is the first system to combine magnetic resonance imaging (MRI) guidance and linear accelerator radiation delivery. These treatments mark the first in Turkey using MRI-guided radiation therapy.
MRIdian MRI-guided radiotherapy represents the latest advance in the field of radiation oncology. The anatomical detail only available with MR soft tissue imaging enables on-table treatment plan adaptation to reshape radiation doses based on the anatomical changes that occur from one day of treatment to the next. Using a novel streaming video perspective, the technology also allows oncologists to visualize and automatically control beam delivery based on the real-time position of the tumor and surrounding organs.
"We are pleased to have commenced Turkey's first MRI-guided radiation therapy program and believe it offers cancer patients in our country a number of distinct benefits over traditional radiation therapy," said Enis Ozyar, M.D., professor, chairman of Acibadem University Department of Radiation Oncology. "MRIdian allows for clinical improvements in visualization and precision daily plan adaptation, and it provides us with the tools to deliver higher and potentially more effective radiation doses."
Acibadem Maslak Hospital is part of the Acibadem Healthcare Group, one of the leading institutions in Turkey in the field of private healthcare services. Comprised of 21 hospitals and 16 medical centers, Acibadem signed a joint partnership with IHH Healthcare in 2012 that enabled them to be a part of world's second largest healthcare chain. Turkey is currently one of the leading countries in health tourism due to the country's advanced diagnostic and treatment services offered.
In addition to treating a full spectrum of cancerous tumors, Acibadem Maslak Hospital intends to explore the benefit of local control, toxicity and survival with MRIdian Linac compared to standard radiotherapy technologies.
For more information: www.viewray.com
November 04, 2026 
